Hospital practices concerning the in-use storage time of (reconstituted) oncology medicines

Dear BOPA Members,

The EDQM (the European Directorate for the Quality of Medicines&Healthcare of the Council of Europe) is conducting a survey following a study from national monitoring activities, which revealed that some hospital pharmacies assign longer in-use storage times to reconstituted anticancer medicines than those specified in the marketing authorisation and summary of product characteristics (SmPC).

The aim of the survey is to assess how common these practices are across Europe, to identify the sources used to justify extended storage times, and to understand the rationale behind them. The final objective is to map current practices and evaluate the potential need for guidance to ensure the safe use of reconstituted medicines.

Your contributions would be extremely valuable to provide EDQM with a comprehensive overview of the situation across Europe. To contribute you can use the following link:

https://survey.edqm.eu/index.php?r=survey/index&sid=751574&lang=en

The deadline for submission is 08 November 2024.

The EDQM assured that the responses will remain confidential.

Thank you for your collaboration.

 

Lead Policy Officer
European Association of Hospital Pharmacists (EAHP)

Latest News

By BOPA Passport pillar on 6th November 2024

Request for membership to create or review content for BOPA Digital SACT passport (Update)

Dear Member, Regarding the earlier communication for registering to become a creator/reviewer of mock prescriptions: This process has been amended and creation/review is open to free associates and above, as…

Read article
By Netty Cracknell on 6th November 2024

Independent Sector Cancer Network (ISCN) Publish NEW Cancer Service Guidelines

The Independent Sector Cancer Network (ISCN) is a strategic quality governance and safety group which aims to improve independard sector cancer provision though effective collaboration and sharing of best practice across the…

Read article
By Joseph Williams on 5th November 2024

New Publication by BOPA Member and AI Specialist Advisory Group (SAG) Co-Chair Pinkie Chambers

From prediction to practice: mitigating bias and data shift in machine-learning models for chemotherapy-induced organ dysfunction across unseen cancers New Publication by BOPA Member and AI Specialist Advisory Group (SAG)…

Read article
By BOPA Executive Committee on 4th November 2024

CRUK Consent Form Updates – MPN and Nivolumab with Relatlimab for melanoma

Dear All, I am happy to inform you that the MPN consent forms have been reviewed and updated. Furthermore, a new consent form has been added  form for Nivolumab with…

Read article